localized prostate cancer
Conditions
Interventions
Total:Intensity-modulated Radiotherapy: 2.7GyX25 fractions to the prostate +/- seminal vesicle +/- prophylactic pelvis lymphnode irradiation (concurrent with 50Gy/25 fractions).
Sponsors
Cancer Hospital & Institute, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Signed informed agreement form; 2. Pathologic confirmed to be prostate adenocarcinoma; 3. Localized disease without extension beyond pelvis; 4. Aged between 50 and 75 years, with Karnofsky score>70; 5. Hgb>=10 g/dl, WBC>=3.5*10^9/L, PLT>=85*10^9/L; 6. AST, ALT and TB<=1.5 normal value, Cr and BUN<=1.0 normal value; 6. Without life-threatening comorbidites.
Exclusion criteria
Exclusion criteria: 1. Having a history of other malignancy (except tumor in situ); 2. Having a history of radiotherapy to the abdomen or pelvis; 3. Concurrent with severe infection or other serious acute diseases; 4. With other uncontrollable complications; 5. Life expectancy< 6 months; 6. Already participating in other clinical trial within 4 weeks; 7. With other potential unfitting conditions which may conflict the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T-PSA and F-PSA;the acute and late gastrointestinal (GI) and genitourinary (GU) toxicity;bNED; | — |
Countries
China
Contacts
Public ContactYueping Liu
Outcome results
None listed